Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-11

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to characterize the safety profile of sotorasib.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

NCT04933695

Non-small Cell Lung Cancer

COMPLETED PHASE2

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE2

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

NCT06582771

Non Small Lung Cancer

RECRUITING PHASE2

Expanded Access of Sotorasib

NCT04667234

Non Small-cell Lung Cancer Locally Advanced Unresectable NSCLC Locally Advanced Metastatic NSCLC

NO_LONGER_AVAILABLE

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

NCT07199010

Non-small Lung Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chinese Participants Treated with Sotorasib

Adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and previously treated with at least 1 prior systemic therapy that have received sotorasib treatment in either location of BOAO Pilot Zone and Hong Kong SAR will be included in this cohort.

The duration of evidence collection is from initiation of sotorasib to the end of study period, up to approximately 4 years from the date of the first available sotorasib use in BOAO Pilot Zone of around August 2021.

Sotorasib

Intervention Type DRUG

Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sotorasib

Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMG 510

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (≥ 18 years) as of the index date.
* KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
* Received at least 1 dose of sotorasib.
* Receipt of at least 1 prior systemic therapy before use of sotorasib.
* Obtained ICF, if required.